AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05899179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Mycobacterium Tuberculosis Fusion Protein
Description: Dosage form:injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm.
Study NCT05899179 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Mycobacterium Tuberculosis Fusion Protein
Description: Dosage form:injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm.
Study NCT05899179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Protein Derivative of Tuberculin
Description: Dosage form:injection. Main ingredients and contents:Pure protein derivatives of tuberculin,0.1ml per bottle.~Usage:0.1ml (5IU) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method.
Study NCT05899179 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Protein Derivative of Tuberculin
Description: Dosage form:injection. Main ingredients and contents:Pure protein derivatives of tuberculin,0.1ml per bottle.~Usage:0.1ml (5IU) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method.
Study NCT06423742 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: The device used for tDCS in this study was DC-Stimulator Plus (NeuroConn GmbH, Ilmenau, Germany). The localization of stimulation area (DLPFC) was determined according to the 10/20 EEG system. Non-conducting, elastic head strap was placed around the head to prevent displacement during stimulation. The recording electrode covered with 5 x 7 cm sized traditional rectangular sponge was soaked with 6-7 mL of 0.9% NaCl saline solution per side and placed on the F3 (anode, left frontal) and F4 (cathode, right frontal) EEG location. Subjects were given 2 mA stimulation intensity for 20 min per session including fade-in and fade-out times for 20 seconds each. Interval between each session was 20 min. Sham procedure has been adopted a Fade In of current, Short Stimulation, Fade Out (FISSFO) protocol that consist of initial ramp up for 20 seconds, 2 mA stimulation for 40 seconds, and 20 seconds for ramp down. To check to impendence, brief current of 110 µA over 15ms every 550ms was delivered.
Study NCT06423742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: The device used for tDCS in this study was DC-Stimulator Plus (NeuroConn GmbH, Ilmenau, Germany). The localization of stimulation area (DLPFC) was determined according to the 10/20 EEG system. Non-conducting, elastic head strap was placed around the head to prevent displacement during stimulation. The recording electrode covered with 5 x 7 cm sized traditional rectangular sponge was soaked with 6-7 mL of 0.9% NaCl saline solution per side and placed on the F3 (anode, left frontal) and F4 (cathode, right frontal) EEG location. Subjects were given 2 mA stimulation intensity for 20 min per session including fade-in and fade-out times for 20 seconds each. Interval between each session was 20 min. Sham procedure has been adopted a Fade In of current, Short Stimulation, Fade Out (FISSFO) protocol that consist of initial ramp up for 20 seconds, 2 mA stimulation for 40 seconds, and 20 seconds for ramp down. To check to impendence, brief current of 110 µA over 15ms every 550ms was delivered.
Study NCT06423742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: The device used for tDCS in this study was DC-Stimulator Plus (NeuroConn GmbH, Ilmenau, Germany). The localization of stimulation area (DLPFC) was determined according to the 10/20 EEG system. Non-conducting, elastic head strap was placed around the head to prevent displacement during stimulation. The recording electrode covered with 5 x 7 cm sized traditional rectangular sponge was soaked with 6-7 mL of 0.9% NaCl saline solution per side and placed on the F3 (anode, left frontal) and F4 (cathode, right frontal) EEG location. Subjects were given 2 mA stimulation intensity for 20 min per session including fade-in and fade-out times for 20 seconds each. Interval between each session was 20 min. Sham procedure has been adopted a Fade In of current, Short Stimulation, Fade Out (FISSFO) protocol that consist of initial ramp up for 20 seconds, 2 mA stimulation for 40 seconds, and 20 seconds for ramp down. To check to impendence, brief current of 110 µA over 15ms every 550ms was delivered.
Study NCT06419933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The SuperKids Program
Description: The SuperKids program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/ treatment
Study NCT04840862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]
Description: Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
Study NCT04840862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin 300mg
Description: After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
Study NCT06196944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Augmentative Alternative Communication Device
Description: Augmentative Alternative Communication Device 3 session for 40 minutes
Study NCT04868864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT scan
Description: Non-enhanced LDCT scans of the thorax will be taken using standard technology on helical CT system
Study NCT06705764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tezepelumab
Description: Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.~Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90
Study NCT06705764 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tezepelumab
Description: Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.~Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90
Study NCT06705764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.91 ml subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.
Study NCT06732687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenics
Description: Calisthenics~Arm Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks.
Study NCT06732687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometrics
Description: Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
Study NCT06732687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined( Calisthenics+ Plyometrics)
Description: Description: Both exercises would be performed. First Calisthenics will be performed and then plyometrics will be performed.
Study NCT06740864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current will be delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) are used throughout the stimulation.
Study NCT06740864 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial alternating current stimulation
Description: Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
Study NCT06735768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS treatment
Description: Brightmind.AI´s rTMS protocol is applied
Study NCT06735768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Determination of motor hotspot and motor treshold
Description: Determination of motor hotspot and motor treshold
Study NCT06735768 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Determination of motor hotspot and motor treshold
Description: Determination of motor hotspot and motor treshold
Study NCT06740981 — intervention group
Intervention type: OTHER
Intervention: Food diary
Description: A food and beverage diary will be collected for five days starting from the initiation of noninvasive ventilation, with caloric and protein intake quantified by a Nutrition Physician Specialist.
Study NCT06740448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea
Description: 200 mL Green Tea
Study NCT06740448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green Tea
Description: 200 mL Green Tea
Study NCT06740448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control (Hot Water)
Description: 200 mL hot water
Study NCT06740448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (Hot Water)
Description: 200 mL hot water
Study NCT06740916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 81-mg aspirin once daily
Description: 81-mg aspirin once daily
Study NCT06740916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 81-mg aspirin twice daily
Description: 81-mg aspirin twice daily
Study NCT06739629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insect porridge
Description: Yellow mealworm porridge
Study NCT06739629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maize Porridge
Description: Maize porridge
Study NCT06751160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Dry Needling will be given to group A along with baseline treatment through following protocol:~Patient will be in prone lying. Sterilized disposable dry needles of 0.25\*60mm will be used. Dry needling will be performed on three points on Hamstring muscle for one minute each. We considered a line between ischial tuberosity and head of fibula to target long head of bicep femoris (60% of line) and short head of bicep femoris (30% of line). Semitendinosus and Semi Membranosus were targeted at a point of 60% of line from ischial tuberosity to medial epicondyl of femur.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks.
Study NCT06751160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft Tissue Mobilization
Description: Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Soft Tissue Mobilization will be given to Group B along with Baseline treatment.~Subject will be in prone lying position with knee bent at 30 to 60 degrees. Soft tissue mobilization will be applied on hamstring muscle through Graston technique. Massage cream will be applied on hamstring muscle and Graston Instrument will be rubbed from gluteal line to politeal fossa 30 times for 60 seconds.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks.
Study NCT06748521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP + X
Description: Eligible participants will receive 1 cycle of R-CHOP therapy with genotyping and ctDNA testing at C1D14. Chemotherapy sensitive patients with C1D14 ctDNA negative or ctDNA LFC ≥ 2 will continue to receive R-CHOP therapy for up to 6 courses. Potentially resistant patients with C1D14 ctDNA positive and LFC \< 2 were stratified by DLBCL genotyping and treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.
Study NCT06748612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine
Description: Whole-cell pertussis pentavalent vaccine (wP-Penta): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate
Study NCT06748612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentavalent vaccine
Description: Whole-cell pertussis pentavalent vaccine (wP-Penta): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate
Study NCT06748612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine
Description: Whole-cell pertussis hexavalent vaccine (wP-Hexa): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate, and inactivated polioviruses to all three poliovirus types: type 1 , 2 and 3
Study NCT06748612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Description: one dose of IPV (0.5 mL) contains inactivated polioviruses to all three poliovirus types: type 1, 2 and 3
Study NCT06748612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent oral polio vaccine (bOPV)
Description: Contain two poliovirus types: type 1 and 3
Study NCT06748612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fractional IPV( fIPV)
Description: The dose of fIPV is 0.1 mL or 1/5th of a full dose
Study NCT06749834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Description: 1. Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，or intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg).~2. Patients within 4.5-9 hours of onset with core/perfusion mismatch confirmed by CTP/MRI, is treated with alteplase for intravenous thrombolysis.
Study NCT06751004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BALLISTIC SIX EXERCISES
Description: Ballistic six exercises will be given to group A and exercises of 3 sets of 10-20 repetitions will be completed, with each series offering 30-60 seconds of rest. The ballistic Six exercise uses resistance-band latex tube and fitness balls.
Study NCT06751004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESISTANCE-BAND EXERCISES
Description: Resistance-band exercises will be given to group B and the duration of training sessions will be 3 sets of 10-20 repetitions
Study NCT06750497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm immobilization
Description: Two days of forearm immobilization
Study NCT06750120 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Family food ration
Description: Monthly household food rations providing 5 daily food groups and a mean of 165 kcal/per capita/day
Study NCT05232630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks.
Study NCT05132686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IER+MED
Description: Over a 6 month period follow a euenergetic Mediterranean diet 5 days per week and a 20% energy restriction over 2 contiguous days as a 70% energy restriction using the same macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
Study NCT05132686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MED/DER
Description: Over a 6 month period follow a Mediterranean diet 7 days per week with a 20% energy restriction 7 days a week using the macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
Study NCT05819541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Oral Granules
Description: Oral montelukast granules, USP powder, or crushed tablets at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.
Study NCT05819541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
Study NCT05819541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
Study NCT05819541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
Study NCT05819541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
Study NCT06750120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal weight counseling
Description: Counseling on health gestational weight gain and post partum weight loss
Study NCT06750120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care includes~1. Usual care: free standard pregnancy, postnatal, and infant care through Ministry of Health services.~2. Enhancements to usual care: Participants in both arms will be enrolled in Maya Health Alliance's free care navigation program. In this program, navigators accompany patients to clinical visits at national hospitals, provide interpretation, and cover emergency transportation cost.
Study NCT04811313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA
Study NCT04811313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal epidural block
Description: regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss
Study NCT06750120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Enhanced usual care includes~1. Usual care: free standard pregnancy, postnatal, and infant care through Ministry of Health services.~2. Enhancements to usual care: Participants in both arms will be enrolled in Maya Health Alliance's free care navigation program. In this program, navigators accompany patients to clinical visits at national hospitals, provide interpretation, and cover emergency transportation cost.
Study NCT06750952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab Combined With Chemotherapy
Description: Ivonescimab injection is an IgG1 subtype humanized bispecific antibody targeting human vascular endothelial growth factor-A (VEGF-A) and programmed death protein-1 (PD-1). It can bind to VEGF-A and PD-1 at the same time, and competitively block the interaction between VEGF-A, PD-1 and their ligands, exerting antitumor activity.